News

The study is a double-blind, placebo-controlled, repeat-dosing multi- center study designed to evaluate the clinical safety and clinical effects of repeat administration of SB-509 in diabetics with mild

The terms of the agreement call for a stock-for-stock merger transaction resulting in Galil Medical becoming a wholly-owned subsidiary of Endocare, and would provide current Endocare stockholders 52%,

This agreement guarantees Kamada a steady supply of raw material that meets the international standards set by the FDA and European Medicines Agency. The suppliers are also required

ArQule and Daiichi Sankyo have entered into a binding letter of intent for an exclusive license, co-development and co-commercialization agreement under which they shall collaborate to conduct research,

New investor, Longitude Venture Partners led the round and was joined by existing investors Adams Capital Management, Quaker BioVentures, Birchmere Ventures, Techno Venture Management, and Draper Triangle Ventures.

According to the company, DiaVis delivers a blend of key antioxidants, including Pycnogenol, and other nutrients found to play a role in helping to combat oxidative stress and

For the first time, European hospitals will have access to a reliable, rapid test for Clostridium difficile, which simultaneously detects and identifies the commonly occurring strains and specifically

Under the service agreement, Stem Cell Sciences (SCS) will create standard culture conditions for CHDI’s mouse embryonic stem (ES) cell lines using its serum-free and feeder-free Esgro Complete

Simultaneous with the financial closing, Psyadon and Schering executed an agreement under which Psyadon will acquire worldwide rights to Schering’s selective dopamine D1 receptor antagonist, ecopipam. The new